Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

Roche will present 46 abstracts at the ASH Annual Meeting, highlighting advancements in haematology. The data showcases the effectiveness of Roche's approved medicines and pipeline progress in treating blood disorders. Hemlibra data demonstrates improved joint health and activity levels in haemophilia A patients. NXT007, a bispecific antibody, shows potential for normalizing haemostasis in haemophilia A, leading to phase III trials. Pre-clinical data for SPK-8011QQ gene therapy shows enhanced haemostatic potency. Lunsumio combined with lenalidomide shows promise as an outpatient treatment for relapsed follicular lymphoma. Lunsumio plus Polivy demonstrates sustained improvements in large B-cell lymphoma. Columvi shows continued superior survival outcomes in relapsed diffuse large B-cell lymphoma. Cevostamab, in combination, induces high response rates and durable remissions in relapsed multiple myeloma, progressing to phase III.